| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| ACCOUNTING | 3,536 | 0 | 3,536 |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| I SHARES MSCI EMERGING MKT | 21,824 | 34,902 |
| I SHARES S&P 500 GROWTH | 35,543 | 181,892 |
| I SHARES S&P 500 VALUE | 44,884 | 121,723 |
| I SHARES RUSSELL 2000 | 17,898 | 50,178 |
| BIOMARIN PHARMACEUTICAL | 45,225 | 72,315 |
| SUPERNUS PHARMACEUTICALS | 16,577 | 43,410 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| QCA FIRST FUND IV, LLC | AT COST | 1,825 | 1,825 |
| HEALTHCARE ASSET NETWORK, INC. | FMV | 101,180 | 160,773 |
| QCA FIRST FUND VI, LLC | AT COST | 62,013 | 62,013 |
| SERENE LLC | AT COST | 143,818 | 143,818 |
| PLANKKSTERS LLC | AT COST | 49,902 | 49,631 |
| EXUBRION PHARMACEUTICALS | AT COST | 9,834 | 9,834 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| ANNUAL REPORT FILING | 15 | 0 | 15 | |
| QCA IV | 20 | 20 | 0 | |
| INVESTMENT EXPENSES - PASS-THROUGH | 819 | 819 | 0 | |
| SERENE | 577 | 577 | 0 | |
| QCA VI | 3,753 | 3,753 | 0 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| AGENCY & INVESTMENT FEES | 300 | 300 | 0 | |
| BANK FEES | 33 | 33 | 0 | |
| CONSULTING FEES | 22,000 | 0 | 22,000 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FOREIGN TAX PAID | 152 | 152 | 0 | |
| OTHER TAXES | 62 | 62 | 0 |